Why I'd BUY this heavily shorted ASX share while it's under pressure

Down 39% in 2024, short sellers think this ASX 200 share has further to fall. I think they're wrong.

| More on:
A little boy measures himself against a ruler and comes up short.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I wouldn't buy just any heavily shorted ASX share.

Short sellers, I presume, will have done their research before betting against a stock's share price.

Their bearish premise could be based on macroeconomic headwinds they believe are about to impact a company's performance. Or it could be based on company-specific issues, like rising costs, falling market share or poor management.

But here's the thing.

Just like investors sometimes buy ASX shares that eventually tumble in value, short sellers sometimes take up positions in stocks that eventually rocket higher.

With that in mind, here's a heavily shorted ASX share I'd buy while it's still under pressure.

An ASX share to buy before it rebounds

The company in question is S&P/ASX 200 Index (ASX: XJO) uranium share Boss Energy Ltd (ASX: BOE).

Boss Energy joined the top ten most shorted ASX 200 shares this week, with short interest standing at 9.5%.

Indeed, with uranium prices trading around US$79.50 a pound, at 10-month lows, two other ASX uranium stocks came in at number 11 and number 12 on this rather ignominious list.

This tells me that rather than buying this ASX share, many short sellers are likely betting against it based on their outlook for uranium prices. After all, it was only back in February that the radioactive metal was trading at 16-year highs of US$106 a pound.

Addressing the macro picture first, I believe short-selling Boss Energy rather than buying the ASX share could backfire in the short term and is even more likely to prove a mistake in the long term.

The nuclear renaissance we're seeing among many major economies – including the United States, China, India, Japan, France and a host of other nations that pledged to triple their nuclear power capacity by 2050 – hasn't gone away.

With some 58 new nuclear reactors currently under construction, the medium to long-term uranium demand remains quite strong. And I am talking quite long-term here.

According to the World Nuclear Association, global uranium demand will likely exceed global supply through to 2040.

As for why I'd specifically buy this ASX share despite the heavy short position, I believe Boss Energy is well placed to outperform in the year ahead.

On 22 April, the ASX 200 uranium stock announced the production of its first drum of uranium at Honeymoon. In July and August, Boss Energy produced 72,516 pounds of the nuclear fuel.

And with commissioning and ramp-up to steady-state production proceeding according to plan, the cost per pound of producing that uranium is going to fall.

"We continue to meet or exceed all of our key targets and are comfortably on track to meet our production guidance," Boss Energy managing director Duncan Craib said last week.

Boss Energy is forecasting Honeymoon production of at least 850,000 pounds of uranium in FY 2025.

And the balance sheet is solid. The ASX 200 uranium stock reported liquid assets of $273 million and no debt as at 30 June.

With the Boss Energy share price down 39% in 2024, closing yesterday at $2.61 a share, buying this ASX share today could deliver some outsized gains in the year ahead.

How outsized?

Well, according to Bell Potter, potentially more than 118%.

Bell Potter recently reaffirmed its buy rating on Boss Energy with a target price of $5.70 a share.

So, this is one heavily shorted ASX share I'd buy today before that potential rally picks up steam.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A business woman looks unhappy while she flies a red flag at her laptop.
Opinions

5 ASX shares I'm avoiding this week

There's warning bells ahead for these stocks.

Read more »

a hand reaches out with australian banknotes of various denominations fanned out.
Dividend Investing

These 2 ASX dividend shares are great buys right now

These defensive names look like strong picks today.

Read more »

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

Hand holding out coal in front of a coal mine.
Energy Shares

Up 25% in 2025: Is Whitehaven Coal still a buy?

After a strong 25% run this year, investors are asking whether Whitehaven Coal still has more upside left.

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Opinions

5 ASX shares I'd buy with $10,000 this week

These are the ASX stocks I have my eye on this week.

Read more »

bull market model with a bull looking at a rising chart
Opinions

By December 2026, $1,000 invested in EOS shares could be worth…

With its share price taking off and contracts piling up, EOS is shaping up as one of the most compelling…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »